Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Other Non-Current Liabilities (2017 - 2025)

Cytokinetics (CYTK) has disclosed Other Non-Current Liabilities for 9 consecutive years, with $27.9 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities changed N/A to $27.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at $27.9 million for FY2025, N/A changed from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $27.9 million at Cytokinetics, up from $1.6 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $174.8 million in Q3 2021, with the low at $408000.0 in Q3 2023.
  • Average Other Non-Current Liabilities over 5 years is $39.6 million, with a median of $8.1 million recorded in 2021.
  • The sharpest move saw Other Non-Current Liabilities plummeted 99.29% in 2022, then surged 16652.0% in 2024.
  • Over 5 years, Other Non-Current Liabilities stood at $4.5 million in 2021, then tumbled by 76.58% to $1.0 million in 2022, then soared by 1106.9% to $12.6 million in 2023, then soared by 730.95% to $104.7 million in 2024, then plummeted by 73.35% to $27.9 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $27.9 million, $1.6 million, and $12.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.